News Esketamine is approved in Europe for treating resistant major depressive disorder BMJ 2019; 367 doi: https://doi.org/10.1136/bmj.l7069 (Published 20 December 2019) Cite this as: BMJ 2019;367:l7069 Article Related content Metrics Responses Peer review Related articles Editorial Esketamine for treatment resistant depression Published: 23 September 2019; BMJ 366 doi:10.1136/bmj.l5572 News Esketamine for treatment resistant depression is not recommended by NICE Published: 28 January 2020; BMJ 368 doi:10.1136/bmj.m329 News NICE reconsiders esketamine for depression Published: 04 September 2020; BMJ 370 doi:10.1136/bmj.m3479 News Depression: EU approves expanded use of esketamine for rapid reduction of symptoms Published: 10 February 2021; BMJ 372 doi:10.1136/bmj.n398 Editorial Ketamine for suicidal ideation Published: 02 February 2022; BMJ 376 doi:10.1136/bmj.o74 See more James Kyle BMJ November 30, 2023, 383 p2834; DOI: https://doi.org/10.1136/bmj.p2834 Nicholas Henry Dyer BMJ November 30, 2023, 383 p2701; DOI: https://doi.org/10.1136/bmj.p2701 Colin Smith BMJ November 30, 2023, 383 p2817; DOI: https://doi.org/10.1136/bmj.p2817 Kuljeet Takhar BMJ November 30, 2023, 383 p2820; DOI: https://doi.org/10.1136/bmj.p2820 Hans Ludwig Herzberg Frankel BMJ November 30, 2023, 383 p2816; DOI: https://doi.org/10.1136/bmj.p2816 Cited by... Depression: EU approves expanded use of esketamine for rapid reduction of symptomsFulltext PDF NICE reconsiders esketamine for depressionFulltext PDF Esketamine for treatment resistant depression is not recommended by NICEFulltext PDF
